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Atherosclerosis is one of the primary causes of cardiovascular disease and mortality. This
chronic immunometabolic disease evolves during decades in humans and encompasses
different organs and immune cell types, as well as local and systemic processes that
promote the progression of the disease. The most frequently used animal model to
study these atherogenic processes and inter-organ crosstalk in a short time frame are
genetically modified mouse models. Some models have been used throughout the last
decades, and some others been developed recently. These models have important
differences in cholesterol and lipoprotein metabolism, reverse cholesterol transport
pathway, obesity and diabetes as well as inflammatory processes. Therefore, the disease
develops and progresses differently in the various mouse models. Since atherosclerosis
is a multifaceted disease and many processes contribute to its progression, the choice
of the right mouse model is important to study specific aspects of the disease. We
will describe the different mouse models and provide a roadmap to facilitate current
and future atherosclerosis researchers to choose the right model depending on their
scientific question.
Keywords: atherosclerosis, cardiovascular disease (CV disease), mouse models, immunometabolic disease,
lipoprotein metabolism, inflammatory signaling, PCSK9 (proprotein convertase subtilisin kexin type 9), Fibrillin 1
BACKGROUND
Atherosclerosis is a chronic immunometabolic disease and remains asymptomatic until a plaque
becomes large enough to obstruct the lumen to cause ischemic pain or ruptures and causes a
myocardial infarction, stroke, or peripheral artery disease. At the early stage, the disease is driven by
the retention of cholesterol-rich, apolipoprotein B-containing lipoproteins at specific predilection
sites such as bifurcations. High level of plasma low-density lipoprotein (LDL)-cholesterol is
the most important risk factor promoting the development and progression of atherosclerosis.
Lipoproteins that accumulate in the arterial wall undergo various modifications, such as oxidation
and carbamylation. These modified lipoproteins and other pro-inflammatory triggers mediate
the activation of vascular endothelial cells (Figure 1). In turn, activated endothelial cells express
adhesion molecules, which bind to and recruit circulating innate and adaptive immune cells,
such as monocytes and T cells (Figure 1). Within the intima, monocytes differentiate into
macrophages and ingest modified lipoproteins, becoming cholesterol-laden foam cells (1). Plaque
macrophages express different scavenger receptors that recognize and mediate the uptake modified
lipoprotein antigens, such as oxidized lipoproteins, hence promoting foam cell formation and a
pro-inflammatory polarization (Figure 1) (2). The excessive storage of cholesterol esters leads to
a defective esterification pathway, thus resulting in a consistent accumulation of free cholesterol
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FIGURE 1 | Model of atherogenesis. This scheme illustrates the development of an atherosclerotic plaque from left to right in a longitudinal section of an arterial
vessel. (1) Upon activation by metabolic or inflammatory triggers, endothelial cells express adhesion molecules (Ad. mol.) that promote the recruitment of immune
cells, such as blood monocytes (Mono). These cells then infiltrate the arterial intima, where monocyte differentiate into macrophages (Macro) and interact with other
immune cells, such as neutrophils (Neutro) and T cells. (2) Increased uptake of modified lipoproteins via scavenger receptors or decreased cholesterol efflux
accelerates the accumulation of intracellular free cholesterol and cholesteryl ester-loaded lipid droplets that promote foam cell formation. (3) Macrophage foam cells
eventually die and fall apart, thereby forming a necrotic core. (4) Advanced, vulnerable plaques can rupture and thereby form an arterial thrombus, which can lead to a
myocardial infarction or stroke. RBC, red blood cell; VSMC, vascular smooth muscle cell.
that forms cholesterol crystals that damage the cells and activate
apoptotic pathways. Efferocytosis, i.e., the phagocytosis of
apoptotic and necrotic cells, gets impaired and promotes
a further accumulation of foam cell debris and the release
of inflammatory mediators that together potentiate the
inflammation of the arterial wall (3). Additionally, foam cells
release enzymes that degrade the extracellular matrix, thus
increasing plaque vulnerability and the eventual risk of rupture,
which would lead to platelet aggregation, blood coagulation
and thrombus formation (Figure 1) (1). The development
and stability of atherosclerotic plaques is also affected by
inflammatory cytokines that are released by different immune
cells, such as TNF-α and IFN-γ (4). These released cytokines
induce an intra-plaque immune response and promote vascular
smooth muscle cells (VSMCs) death, thus destabilizing the
matrix of the plaques. Moreover, other cells and organs also
contribute to the immunometabolic dysregulation happening
during atherosclerosis development. Therefore, it is advisable to
compare the different atherosclerosis mouse models and choose
one that resembles the aspects of the human pathology as good
as possible.
ANIMAL MODELS
The pathophysiology of atherosclerosis in humans is a complex
process that is triggered by various risk factors, including
aging, hyperlipidemia, hypertension and diabetes, which lead
to an immunometabolic dysregulation. The study of the
immunometabolic processes and molecular mechanisms driving
the disease requires animal models that mimic the human
pathophysiology. Notably, there is no perfect animal model that
recapitulate all the features of the human disease. Several animal
models have been studied for atherosclerosis research over the
last decades, and all of them show advantages and disadvantages.
Different animal models can be chosen depending on the focus
of the research. In terms of human physiology similarities and
clinical relevance, non-human primates are the best model for
atherosclerosis investigation. However, non-human primates are
expensive to maintain, they develop the disease over a long time,
there is a high risk of infections, and they have high ethical
hurdles (5, 6). Alternative animal models should be cheaper,
easier to handle and reproduce the human disease as good as
possible (7). Moreover, they should be appropriate to perform
genetic, pharmacological and/or interventional studies.
OF MICE AND MEN
Mouse models meet these criteria at least in part and are thus are
the most common animal model used for atherosclerosis studies.
Nevertheless, mice also display major genetic and physiological
differences compared to humans (8). One of the most evident
difference between mice and humans resides in the lipoprotein
metabolism. Mice are considered as a high-density lipoprotein
(HDL) models since most of the cholesterol is transported in
HDL particles, and not in LDL as in humans. Consequently, mice
carry most plasma cholesterol in HDL particles and overall have
massively lower cholesterol levels, which confers atherosclerosis
protection due to an improved reverse cholesterol transport
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pathway (9). One reason for this difference is the lack of the
cholesteryl ester transfer protein (CETP) in mice. In fact, CETP
promotes the transfer of cholesterol ester from HDL to very low-
density lipoproteins (VLDL) and of triglycerides from VDLD to
HDL. Humans display a high expression CETP, which in turn
leads to increased VLDL- and LDL-cholesterol levels.
Another important difference between mice and humans
resides in the different bile acids composition. Additionally to the
classical bile acid species that are synthesized in humans, mice
produce α- and β-muricholic acids, which are more hydrophilic
and thus reduce the uptake of cholesterol in the intestine (10).
Moreover, the different composition of secondary and tertiary
bile acids (e.g., tauro vs. glycin conjugation) and increased
synthesis of bile acids is another reason for an improved
reverse cholesterol transport and fecal cholesterol excretion
in mice (11). These differences in lipoprotein metabolism
and bile acids composition confer the mice a resistant to
develop atherosclerosis.
To bypass these limitations and provide an appropriate model
for the pathophysiology of the disease, dietary and genetic
manipulations were developed to generatemousemodels suitable
for atherosclerosis studies. The standard chow diet of mice
usually contains a low content of cholesterol (0.02–0.03%) and
fats (5–6%). This low lipid content does not suffice to promote
the development of atherosclerosis (12). Therefore, scientists
use ‘humanized diets’, such as the Western-type, containing
around 21% fat and 0.15% cholesterol, or the atherogenic diets,
which contain more than 1% cholesterol but the same amount
of fat. The administration of a high-fat-diet does not induce
atherogenesis in most wild-type mouse strains, but it efficiently
induces disease development in atherosclerosis-prone genetic
mouse models.
These atherosclerosis-prone genetic mouse models were
generated by targeting different genes, and they all trigger
atherosclerosis development by altering the lipoprotein profile
toward an increased VLDL- and LDL-cholesterol content,
thus generating a lipoprotein profile that is comparable to
humans (13–17).
Despite the disease development, the predisposed sites for
lesion development differ between mice and humans. Plaques
in humans preferentially develop in the coronary and carotid
arteries, and progress to larger fibrous atheroma. In mice, lesions
are mainly localized in the aortic sinus, proximal aorta and
aortic arch and brachiocephalic trunk, and do not progress to
very advanced stages (18). In fact, even genetically altered mice
do not develop plaque rupture or coronary lesions leading to
myocardial ischemia or infarction. In this review, we will describe
the different transgenic mouse models and provide a roadmap to
guide future researchers to choose an adequate model based on
the scientific question that needs to be addressed (Figure 2).
ATHEROGENIC MOUSE STRAINS
Although mice are classified as high-density lipoprotein models,
there are important strain-specific differences in lipoprotein
metabolism and inflammatory susceptibility. BALB/c, C3H
strains have comparable HDL levels, while the C57Bl/6 strain
has much lower HDL levels (19). Additionally, C57Bl/6 mice
become obese, diabetic and susceptible to lesion development
when fed with an atherogenic diet (20). Another important
feature that makes the C57BI/6 mice an ideal model for the study
of atherosclerosis and metabolic syndrome is the polarization
toward the Th1 profile. C57Bl/6 mice contain T cells that mainly
produce Th1 cytokines, especially high interferon-γ (IFN-γ),
while other strains such as the BALB/c mice release more Th2
cytokines and less IFN-γ (21). The Th1 profile of C57Bl/6 mice
makes the model even more pro-atherogenic. Indeed most of
the pathogenic T cells in atherosclerosis show a Th1 profile,
characterized by the production of high levels of IFN-γ that
activate monocytes/macrophages and dendritic cells, increase the
expression of matrix metalloproteinases and prevent the collagen
disposition from VSMCs, thus destabilizing the fibrous cap and
promoting lesion development (22).
CHOLESTEROL AND LIPOPROTEIN
METABOLISM
Despite of the propensity of the C57Bl/6 strain to develop the
disease, different strategies were produced to increase LDL-
cholesterol and thereby the atherosclerotic susceptibility of the
C57Bl/6 strain, including the disruption of the low-density
lipoprotein receptor (Ldlr-/-), the deletion of the apolipoprotein
E (Apoe-/-), or the ectopic introduction of a mutant protein
convertase subtilisin/kexin type 9 (Pcsk9) gene.
APOE is part of the structure of chylomicrons remnants,
VLDL and HDL, and it binds to the LDLR, VLDL receptor
(VLDLR) and LDLR-related protein (LRP) in the liver to facilitate
the clearance of plasma chylomicrons and VLDL remnants.
Consequently, the genetic deletion of Apoe in mice results in
increased levels of plasma cholesterol. Apoe knockout mice show
a significant increase of total plasma cholesterol compared to
wild-type mice under chow diet: 400–600 and 75–110 mg/dl,
respectively (23). Of note, humans usually have total plasma
cholesterol levels below 200 mg/dl; while levels over 240 mg/dl
are considered to be high and are commonly related to familial
hypercholesteremia (i.e., mutations in the LDL- or PCSK9
gene). That explains why the deletion of Apoe is sufficient to
drive a massive hypercholesterolemia under normal diet and to
develop spontaneous lesions. Feeding Apoe-/- mice with a high
cholesterol diet additionally increases plasma cholesterol levels
above 1,000 mg/dl, thus driving an extensive and accelerated
atherosclerosis development. Lesion distribution in Apoe–/–
mice are similar to humans, with a predominance in the aortic
root, carotid artery, and aortic branches. However, the Apoe–/–
model shows a different lipoprotein profile from humans since
the majority of plasma cholesterol is carried by VLDL and
chylomicrons particles, whereas it is mainly transported by
LDL in humans. Another limitation of this mouse model is
that despite the accelerated atherosclerosis development, the
lesions rarely rupture and hence do not lead to thrombosis,
whereas vascular occlusion is common in humans (24). In
humans, different isoforms of APOE are linked to altered
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FIGURE 2 | Roadmap to facilitate the choice of an atherosclerotic mouse model. This scheme should help current and future researchers to choose the most
appropriate atherosclerotic mouse model based on their specific research question.
lipoprotein profiles and increased cardiovascular mortality (25).
Individuals carrying the APOE4 allele have more predisposition
to develop cardiovascular disease compared to the APOE2
and APOE3 isoforms. In fact, the APOE4 isoform increases
oxidative stress and inflammation, hence promoting disease
development (26).
A model closer to the human situation to study altered
cholesterol metabolism is the Ldlr knockout mouse. The LDLR
is a membrane receptor located on the surface of many cell types
and its function is to mediate the endocytosis of circulating LDL.
The genetic deletion of the Ldlr increases cholesterol levels to
200–300 mg/dl on chow diet, and to about 1000 mg/dl on an
atherogenic diet (15). The lesions preferentially develop in the
proximal aorta at early stages and along the distal aorta at more
advanced stages (27). Themain aspect that makes Ldlr a favorable
model to study cholesterol metabolism over the Apoe knockouts
is its closer resemblance to human hypercholesterolemia since
most cholesterol is transported by LDL particles (28). In humans,
over 600 mutations of the LDLR gene have been reported,
several of them causing familial hypercholesterolemia, a frequent
genetic disorder associated with high levels of LDL-cholesterol
and atherosclerosis development (29).
REVERSE CHOLESTEROL TRANSPORT
In the reverse cholesterol transport (RCT) peripheral cholesterol
is transferred to HDL particles and then transported to the liver.
Within the liver it can then be further metabolized, be converted
to bile acids, or be directly excreted via the bile. RCT is therefore
regulated at various different sites, including the cholesterol eﬄux
in peripheral tissues and cells, the exchange of lipids between
lipoproteins in the blood, and the uptake, metabolization and
biliary excretion in the liver (30).
APOE plays a central role in peripheral and hepatic RCT
(31). Additionally, macrophages synthesize APOE and promote
cholesterol eﬄux, and interestingly the macrophage-specific
deletion of Apoe affects peripheral RCT in vivo (32–34).
Moreover, APOE-positive macrophages promote proper RCT in
Apoe knockout mice (34). Therefore, the Apoe deletion does
affect both peripheral and hepatic RCT. Given the fact that
the lipoprotein profile of Ldlr–/– mice is closer to humans
and considering the presence of APOE in the system, the Ldlr
knockout is the favored model for RCT and lipoprotein studies.
Another suitable model is the Apoe∗3-Leiden.CETP mouse
line. This model has increased VLDL/LDL-cholesterol because of
the expression of a human CETP, reduced peripheral cholesterol
eﬄux, and severe atherosclerosis development (35). Moreover,
Apoe∗3-Leiden.CETP mice fed a high-fat high-cholesterol diet
for 6 months mimic changes in lipid profiles observed in humans
suffering from the metabolic syndrome, and may therefore be the
preferred model to study age-related changes in lipid metabolism
and reverse cholesterol transport (36, 37).
OBESITY AND TYPE-2 DIABETES
Obesity, insulin resistance and type-2 diabetes are reaching
epidemic proportions world-wide, correlate with atherosclerosis
development, and are strong predictors of cardiovascular
mortality (38). Currently, there is no ideal mouse model that
resembles all features of human diabetes, although several
models have been established to study diabetes-accelerated
atherosclerosis development, including genetic manipulations
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and specific diets (39). Diabetogenic diets that are rich in
fats and sucrose induce obesity in C57Bl/6 mice, making this
strain ideal to study the development of type-2 diabetes and
atherosclerosis (40). Ldlr–/–mice aremore susceptible to develop
diabetes compared to the Apoe–/– mice and the control wildtype
mice under diabetogenic diet feeding. In fact, Ldlr–/– mice
have an increased body weight caused by an accumulation of
subcutaneous adiposity, have high glucose levels and develop an
insulin resistance upon diabetogenic diet challenge (41). This
diabetic phenotype is not observed in Apoe–/– mice, possibly
due to an increased rate of hepatic fatty acid oxidation (41).
Conversely, on a high fat diet, both Apoe–/– and Ldlr–/– mice
develop features of type 2 diabetes and promote atherosclerosis
development (42, 43). Therefore, the choice of the diet is very
important in this context.
Further models were generated by crossbreeding genetic
models of type-2 diabetes, such as leptin (ob/ob) and leptin
receptor (db/db) deficient mice, with atherosclerotic mouse
models. These genetic models enable the study of the disease
development under chow diet (39). Leptins are hormones
synthesized by adipocytes, released into the bloodstream, and
exerting their main functions by binding to leptin receptors
at the hypothalamus to regulate the appetite and thus food
intake. Moreover, leptins increase the energy expenditure that
translate into an elevation in body temperature and increase
in oxygen consumption. Therefore, deficiency of leptin or
the leptin receptor leads an impaired energy expenditure and
increased food intake, and thus to obesity (44, 45). Moreover,
genetic deficiency of the leptin axis impairs the immune system
and increases the susceptibility to infections (46). Thus, leptin
or the leptin receptor-deficient mice display common features
of the immuno-metabolic dysfunction that are observed in
obesity and diabetes mellitus. Mice that develop both diabetes
and atherosclerosis are a good model for the study diabetes-
accelerated atherosclerosis development. For example, Apoe–
/– db/db mice develop obesity, hyperinsulinemia, dyslipidemia
and have a fast atherosclerosis development at 20 weeks of
age compared to the control Apoe–/– mice (47). Ldlr–/– ob/ob
mice get obese and show hyperglycemia, hypercholesterolemia
and spontaneous lesions development under chow diet (48). In
conclusion,multiplemousemodels can be used to study diabetes-
accelerated atherosclerosis, but the interpretation of the data has
to be cautious given the various functions of leptin in many
physiological processes. We refer to the review of Wu and Huan
for further information on this topic (39).
INFLAMMATORY PROCESSES
Inflammatory and immune processes play an important function
in early steps of plaque formation, but also in advanced
stages as reveal by the recent CANTOS trial (49). Lipoprotein
oxidation, endothelial cell activation, macrophage activation
and impaired efferocytosis, VSMCs proliferation, and platelet
aggregation are some of the best characterized processes that
contributes to the arterial wall inflammation, lesion expansion,
and atherothrombosis. APOE is a multifunctional protein that
affects each of these inflammatory processes. Functional APOE
protein inhibits lipoproteins oxidation, while Apoe–/– mice
display increased peroxidation of lipoproteins (50). Apoe–/–
mice also show elevated levels of endothelial cell adhesion
molecules, thus triggering the recruitment of monocytes and
thymocytes into the subintimal space (23, 51). Moreover, APOE
inhibits VSMC proliferation and migration, and consequently
Apoe–/– mice display increases proliferation and migration of
VSMCs (52). Additionally, APOE inhibits platelet aggregation,
hence displaying an additional anti-atherogenic function (53).
Efferocytosis, the phagocytic clearance of dead cells and
cellular debris, plays important functions in the resolution of
inflammation and is mainly mediated by macrophages and other
immune phagocytes (54). The APOE protein has been shown
to exert important functions in this process both in vivo and in
vitro (55). Indeed, APOE promotes the ingestion of apoptotic
cells in macrophages, and thus Apoe-deficient mice display
impaired efferocytosis and an accumulation of apoptotic cells and
cellular fragments in the vessel wall, further promoting lesion
development. These anti-inflammatory properties of APOE,
combined with its impact on lipoprotein metabolism, explain
why Apoe knockout mice display a very strong development
of atherosclerosis compared to other mouse models. Therefore,
other models with a functional APOE protein, such as the
Ldlr–/–, should be the primary choice to study inflammatory
processes in atherosclerosis development.
IMMUNOMETABOLIC REGULATION
Currently, one of the most interesting research questions is
to assess the impact of inflammatory and immune processes
on lipid and lipoprotein metabolism, and vice versa. The use
of the Apoe–/– or Ldlr–/– models to address this question is
limited due to their strong impact on inflammatory processes
and/or lipoprotein metabolism. Another model that has been
developed recently by two different groups are the PCSK9-AAV
mouse lines (16, 17). These mice have no genetic modifications
and express APOE and LDLR at normal levels. Nevertheless,
the introduction of a mouse or human gain-of-function PCSK9
mutant leads to increased total plasma cholesterol (above
1,000 mg/dl) as well as VLDL- and LDL-cholesterol, and the
development of atherosclerosis upon Western diet feeding.
One further advantage of these lines is that a single adeno-
associated virus (AAV) injection is sufficient to generate new
mouse models in a much quicker time compared to conventional
crossbreeding to Apoe–/– or Ldlr–/– mice. Another advantage
is that immunometabolic processes can be studied without
the confounding effects from the lack of APOE or LDLR.
Although the use of AAVs seems to be pretty save and without
pathogenicity, one might still consider a possible anti-viral host
immune response of the organism (56).
ATHEROTHROMBOTIC STUDIES
A clear limitation of the above described mouse models is that
despite developing atherosclerotic lesions, these lesions rarely
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progress to advanced stages with atherothrombotic vascular
occlusion that are observed in humans. Consequently, no
spontaneous plaque rupture is observed in these mouse lines. To
overcome this limitation a group of Belgium scientists developed
and characterized a very interesting mouse model that displays
many features of advanced atherosclerotic plaques (57). The
mouse model was created by crossbreeding mice with a mutant
fibrillin-1 allele (Fbn1C1039G) with Apoe knockout mice, thus
generating Apoe−/− Fbn1C1039G+/− mice. In these mice, the
Fbn1mutation leads to the fragmentation of elastic fibers, which
in turn promotes arterial stiffening and the development of
large vulnerable atherosclerotic plaques that eventually rupture
(58). Moreover, these mice display increased inflammation and
degradation of the extracellular matrix within plaques, and an
increased blood-brain barrier (BBB) permeability that leads to
the development of xanthomas in the brain upon prolonged
exposure to a Western diet (58, 59). Given its strong phenotype
and clinical relevance, this line is currently the most interesting
genetic mouse model to study advanced atherosclerosis and
atherothrombosis in myocardial infarction or ischemic stroke.
Another mouse model that promotes plaque destabilization
and stimulates plaque rupture as well as spontaneous
atherothrombosis consists of Apoe-deficient mice fed with
a high-fat diet for 4 weeks and a subsequent infusion of
angiotensin II for 4 weeks. The continuous infusion of
angiotensin II accelerates the destabilization and vulnerability
of the plaques as well as abdominal aortic aneurysm (60).
Angiotensin II increases the blood pressure, recruits monocytes,
activates macrophages and increases the oxidative stress (61).
Therefore, the Apoe-deficient mice fed with high-fat diet and
subsequent angiotensin II infusion represents an alternative
model to study advanced atherosclerosis.
CONCLUSION
The mouse model continues to be the best model organism to
decipher the underlying genetic, epigenetic and environmental-
induced mechanisms leading to disease development and
progression. The Ldlr knockout model resembles the human
lipoprotein profile pretty well and is therefore a suitable model
to study cholesterol and lipoprotein metabolism. Even closer
to the human profile are the Apoe∗3-Leiden.CETP mice, which
are certainly the model of choice to study human CETP but
also changes in lipid profiles that are also observed in humans
suffering from the metabolic syndrome. Obesity and insulin
resistance are often associated with type 2 diabetes and increase
the risk to develop atherosclerosis. Ldlr and Apoe knockout
mice alone or in combination with a leptin or leptin receptor
deficiency are appropriate to evaluate the metabolic syndrome
in diet-induced studies or under normal chow, respectively.
Inflammation is another important contributor of the disease
development and the Ldlr–/–model should preferentially be used
over the Apoe–/– mice, although other newer models such as the
PCSK9-AAV approach offer an attractive alternative. Finally, the
Apoe −/− Fbn1C1039G+/− mouse line is emerging as a new model
to study atherothrombosis, myocardial infarction, and ischemic
stroke. These mice form large and vulnerable atherosclerotic
plaques that eventually rupture. In conclusions, the study of the
diverse processes promoting atherosclerosis requires different
mouse models, and the provided roadmap should facilitate
current and future researchers to choose an adequate mouse
model for their studies (Figure 2).
PERSPECTIVE
Currently, a very exciting field is to explore the role of
long non-coding RNA (lncRNA) in atherosclerosis and
cardiovascular diseases (62). For example, the lncRNA LeXis
regulates hepatic lipid accumulation and plasma cholesterol
levels, and thereby decreases atherogenesis in Ldlr knockout
mice (63), and MeXis, a lncRNA that is highly expressed
in mouse macrophages, promotes macrophage cholesterol
eﬄux, HDL-driven reverse cholesterol transport, and thus
reduces macrophage foam cell formation and atherosclerosis
development (64). Notably, another lncRNA, CHROME,
has been identified as an alternatively regulator of the
cholesterol eﬄux in primates and its levels are elevated in
plasma and atherosclerotic lesions of individuals with coronary
artery disease (65), highlighting the translational value of
mouse studies.
Future studies aimed at identifying and describing new
triggers and mechanisms regulating atherosclerosis development
will develop novel mouse models to address their specific
questions. Already now most studies are using tissue-specific
overexpression or knockout mouse models, but also starting
to address the function of specific mutations and not yet
well-described posttranslational protein modifications, such as
SUMOylation, in atherogenesis and cardiovascular diseases
(66–70). Moreover, the incredibly fast development of the
Crispr/Cas9 system led to the development of new mouse
and also larger animal models to study atherogenesis and will
continue to accelerate basic and translational cardiovascular
research (71–76).
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